Indoco Remedies Ltd Testing Facility Undergoes U.S. FDA Pre-Approval Inspection
Indoco Remedies Ltd confirmed that its testing facility located in Chhatrapati Sambaji Nagar (Aurangabad) underwent a Pre-Approval Inspection by the U.S. Food and Drug Administration (U.S. FDA).The inspection was conducted by the U.S. FDA between April 08, 2026, and April 10, 2026. The company reported that the review concluded successfully, resulting in zero Form 483 observations.
The facility testing conducted in Chhatrapati Sambaji Nagar is a key operational site for Indoco Remedies Ltd.
Key details regarding the inspection are summarized below:
| Detail | Information |
|---|---|
| Facility Location | Chhatrapati Sambaji Nagar (Aurangabad) |
| Inspecting Body | U.S. Food and Drug Administration (U.S. FDA) |
| Inspection Period | April 08, 2026 to April 10, 2026 |
| Outcome | Zero Form 483 observations |
INDOCO Stock Price Movement
Today, Indoco Remedies Limited shares rallied by 4.32%, closing at ₹211.60 following strong momentum in the pharmaceutical sector. The stock saw high trading activity, recording a volume of 52,995 shares and finishing near its daily high of ₹214.00.Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.